Image optimize LCP
  • Add description, images, menus and links to your mega menu

  • A column with no settings can be used as a spacer

  • Link to your collections, sales and even external links

  • Add up to five columns

  • janvier 08, 2018 2 lire la lecture

    Tranexamic acid (TXA) has been around since the 1960s, when a wife-and-husband research team from Japan discovered how powerful the drug could be for treating severe bleeding. As with many other great discoveries, it took some time before the scientific community and public took it seriously as a crucial, potentially lifesaving treatment for postpartum hemorrhage (PPH), the leading cause of maternal mortality.


    PPH is defined as blood loss of more than 500mL after vaginal birth, more than 1,000mL after caesarean section, or any blood loss that leads to hemodynamic instability. It’s a major health problem, especially in low-income countries, but is fairly treatable and death is preventable with the right treatments given at the right times. Preventing death from PPH means reducing global inequalities in maternal health outcomes and reducing the burden on already struggling health systems. It means healthier moms, healthier babies, more productive lives, and numerous social and economic benefits to society.


    The WHO in 2012 issued a conditional recommendation to use TXA when uterotronics fail to control bleeding or if the bleeding is believed to be because of trauma. However, in 2017, after the results from the large, randomized controlled WOMAN trial were published, the WHO updated some key recommendations regarding the use of TXA. Some main updates include:

    • TXA should be considered part of the standard comprehensive PPH treatment package and for use in all cases of PPH

    • TXA should be readily available at all times in delivery and postpartum areas of facilities providing emergency obstetric care

    • TXA should be administered within 3 hours of birth. Benefits decrease by 10% every 15 minutes, and there appears to be no benefits after 3 hours.

    Acknowledgement from the WHO and updates to its recommendations is certainly an important step, but policymakers, healthcare workers, community leaders, and many other stakeholders still have work to do to ensure that the introduction of TXA is successful. This includes working TXA into national policy, training healthcare workers to properly recognize PPH and administer TXA, and ensure proper monitoring and data availability so we can continue to research and improve treatment.

    By Vivian Shih

    Laisser un commentaire

    Les commentaires sont approuvés avant leur publication.


    Voir l'article entier

    NASG or TANN for postpartum hemorrhage CE-marked device
    Comment fonctionne réellement le NASG pour arrêter l’hémorragie et inverser le choc ?

    octobre 29, 2024 2 lire la lecture

    Le TANN (en espagnol) ou NASG est un dispositif de premiers secours obstétricaux. Il s'agit d'une grosse boule de mousse dense cousue solidement dans un rectangle de mousse, le tout conçu pour être bien ajusté autour de l'utérus et serré avec du velcro cousu.
    Voir l'article entier
    The bubble CPAP reducing neonatal mortality by 27 percent
    La CPAP à bulles réduit la mortalité néonatale de 27 %

    septembre 04, 2024 2 lire la lecture

    Expérience nigériane avec un projet pilote dans 7 hôpitaux utilisant le CPAP à bulles.
    Voir l'article entier
    DreamWarming, infant warming mattress, infant transport mattress, infant hypothermia solution
    Une innovation dans la chaîne du chaud : le DreamWarmer

    juin 24, 2024 2 lire la lecture

    Le matelas chauffant (constitué de bandes de matériau à changement de phase) peut rester chaud pendant 6 heures ou plus. C'est un matelas flexible qui peut être utilisé en conjonction avec le contact peau à peau ou avec la méthode mère kangourou.
    Voir l'article entier